Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
Crossref DOI link: https://doi.org/10.1186/s13023-017-0565-9
Published Online: 2017-01-14
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guérard, N.
Morand, O.
Dingemanse, J.
Funding for this research was provided by:
Actelion Pharmaceuticals